Blog

Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial

Jul 9, 2024 | blog

Baptist Hospital of Miami is the second web site to carry out scientific procedures as a part of the Company’s Pivotal Human Clinical Trial.

The scientific trial is anticipated to assist the longer term submission to the FDA for the commercialization of the LIBERTY ® Endovascular Robotic Surgical System.

BRAINTREE, Mass., July 09, 2024 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: NASDAQ:) at the moment introduced that Baptist Hospital of Miami, which incorporates Miami Cardiac & Vascular Institute and Miami Cancer Institute, has accomplished its first scientific process in a affected person using the LIBERTY ® Endovascular Robotic Surgical System. The scientific case was carried out shortly after final week’s announcement relating to the participation of Baptist Hospital of Miami as a scientific trial web site. Baptist Hospital is the second scientific web site to carry out a scientific process, following the announcement earlier this week of the primary scientific case at Brigham & Women’s Hospital.

The principal investigator at Baptist Hospital of Miami is Dr. Ripal Gandhi, MD, FSVM, FSIR, who additionally carried out this scientific case. The trial is a part of the Investigational Device Exemption for LIBERTY ®, and the Company expects its outcomes will assist the longer term submission to the FDA and subsequent commercialization.

We are very excited to have a hospital of the caliber of Baptist Hospital of Miami performing scientific circumstances. It may be very encouraging to see the progress of our scientific examine, as inside a few weeks we now have two websites actively enrolling sufferers, commented Harel Gadot, CEO, President and Chairman of Microbot Medical.    

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a clinical- stage medical system firm that focuses on transformational micro-robotic applied sciences, with the objectives of bettering scientific outcomes for sufferers and growing accessibility via the pure and synthetic lumens throughout the human physique.

The Investigational LIBERTY ® Endovascular Robotic Surgical System goals to enhance the best way surgical robotics are being utilized in endovascular procedures at the moment, by eliminating the necessity for big, cumbersome, and costly capital tools, whereas decreasing radiation publicity and doctor pressure. The Company believes the LIBERTY ® Endovascular Robotic Surgical System’s distant operation has the potential to be the primary system to democratize endovascular interventional procedures.

Further details about Microbot Medical is on the market at http://www.microbotmedical.com.

Safe Harbor
Statements to future monetary and/or working outcomes, future development in analysis, expertise, scientific improvement, and potential alternatives for Microbot Medical Inc. and its subsidiaries, together with different statements concerning the future expectations, beliefs, objectives, plans, or prospects expressed by administration, represent forward-looking statements throughout the which means of the Private Securities Litigation Reform Act of 1995 and the Federal securities legal guidelines. Any statements that aren’t historic truth (together with, however not restricted to statements that include phrases reminiscent of will, believes, plans, anticipates, expects and estimates) must also be thought-about to be forward-looking statements. Forward-looking statements contain dangers and uncertainties, together with, with out limitation, market situations, dangers inherent within the improvement and/or commercialization of the LIBERTY ® Endovascular Robotic Surgical System, the end result of its research to guage the LIBERTY ® Endovascular Robotic Surgical System, uncertainty within the outcomes of pre-clinical and scientific trials or regulatory pathways and regulatory approvals, together with whether or not the Company’s pivotal examine in people is profitable, any failure or lack of ability to recruit physicians and clinicians to function main investigators to conduct regulatory research which may adversely have an effect on or delay such research, disruptions ensuing from new and ongoing hostilities between Israel and the Palestinians and different neighboring international locations, any lingering uncertainty ensuing from the COVID-19 pandemic, want and skill to acquire future capital, and upkeep of mental property rights. Additional data on dangers dealing with Microbot Medical may be discovered below the heading Risk Factors in Microbot Medical’s periodic studies filed with the Securities and Exchange Commission (SEC), which can be found on the SEC’s web page at www.sec.gov. Microbot Medical disclaims any intent or obligation to replace these forward-looking statements, besides as required by legislation.

Investor Contact:

Michal Efraty

IR@microbotmedical.com

MoneyMaker FX EA Trading Robot

powered by qhost365.com

Investing.com